This is a demo store. No orders will be fulfilled.

Enavatuzumab (anti-TWEAKR) - Primary antibody, specific to TNFRSF12A, Human IgG1, AGONIST of Tumor necrosis factor receptor superfamily member 12A agonist, AGONIST of Tumor necrosis factor receptor superfamily member 12A agonist

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Human
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab183422
Grouped product items
SKU Size
Availability
Price Qty
Ab183422-100μg
100μg
10
$69.90
Ab183422-1mg
1mg
4
$349.90
Ab183422-5mg
5mg
1
$929.90
Ab183422-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,489.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Enavatuzumab (anti-TWEAKR) - Primary antibody, specific to TNFRSF12A, Human IgG1, AGONIST of Tumor necrosis factor receptor superfamily member 12A agonist
Synonyms CD 266 antibody | CD266 antibody | CD266 antigen antibody | FGF inducible 14 antibody | FGF-inducible 14 antibody | Fibroblast growth factor inducible immediate early response protein 14 antibody | Fibroblast growth factor-inducible immediate-early respon
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity TNFRSF12A
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type AGONIST
Mechanism of action AGONIST of Tumor necrosis factor receptor superfamily member 12A agonist
Product Description

Enavatuzumab (anti-TWEAKR) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab (anti-TWEAKR) induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab (anti-TWEAKR) can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab (anti-TWEAKR) inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 26.7 kDa (Light Chain) & 51.2 kDa (Heavy Chain), under reducing conditions; 194.1 kDa, under non-reducing conditions.
Purification Method Protein A purified
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 1062149-33-0

Associated Targets(Human)

TNFRSF12A Tbio Tumor necrosis factor receptor superfamily member 12A (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Enavatuzumab (anti-TWEAKR) (Ab183422) - Flow Cytometry
Flow Cytometry analysis of HT-29 cells labelling TWEAKR (red) with Enavatuzumab (anti-TWEAKR) (Ab183422). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Enavatuzumab (anti-TWEAKR) (Ab183422) - Flow Cytometry
Flow Cytometry analysis of MCF-7 cells labelling TWEAKR (red) with Enavatuzumab (anti-TWEAKR) (Ab183422). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Enavatuzumab (anti-TWEAKR) (Ab183422) - SEC
The purity of Enavatuzumab (anti-TWEAKR) (Ab183422) is more than 95% verified by HPLC.

Enavatuzumab (anti-TWEAKR) (Ab183422) - Flow Cytometry
Transfected with Human TWEAKR protein of HEK293 cells were stained with Enavatuzumab (anti-TWEAKR) (Ab183422) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, the EC50 for this effect is 46.94 nM.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number Certificate Type Date Item
ZJ24F0505694 Certificate of Analysis May 16, 2024 Ab183422
ZJ24F0505696 Certificate of Analysis May 16, 2024 Ab183422
ZJ24F0505700 Certificate of Analysis May 16, 2024 Ab183422

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.